




Rec'd PCT/PTO 22 JUN 2005
FCI/EPUS/14755

EPO3/14755



INVESTOR IN PEOPLE



The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

I also certify that the attached copy of the request for grant of a Patent (Form 1/77) bears an amendment, effected by this office, following a request by the applicant and agreed to by the Comptroller-General.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.

**PRIORITY
DOCUMENT**

SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)

Signed


Andrew King

Dated 20 November 2003

BEST AVAILABLE COPY

Patents Form 1/77

Patents Act 1977
(Rule 16)



The
**Patent
Office**

Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form.)

27DEC02 E773390-2 D00524
P01/7700 0.00-0230034.1

1 / 77

PCT/EP 02 / 1 4 7 5 5

The Patent Office

Cardiff Road
Newport
Gwent NP10 8QQ

1.	Your reference	G-32840/P1/BCK		
2.	Patent application number (The Patent Office will fill in this part)	23 DEC 2002		0230034.1
3.	Full name, address and postcode of the or of each applicant (underline all surnames)	BIOCHEMIE GESELLSCHAFT MBH A-6250 KUNDL, TIROL AUSTRIA		
	Patent ADP number (if you know it)			
	If the applicant is a corporate body, give the country/state of its incorporation	AUSTRIA		
4.	Title of invention	00339929001 Organic compounds		
5.	Name of your agent (if you have one) "Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode)	Novartis Pharmaceuticals UK Limited Patents and Trademarks Wimblehurst Road Horsham West Sussex RH12 5AB		
	Patents ADP number (if you know it)			
6.	If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (if you know it) the or each application number	Country	Priority application number (if you know it)	Date of filing (day/month/year)
7.	If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application	Number of earlier application		Date of filing (day/month/year)
8.	Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer 'Yes' if:	Yes		
	a) any applicant named in part 3 is not an inventor, or			
	b) there is an inventor who is not named as an applicant, or			
	c) any named applicant is a corporate body.			
	(see note (d))			

BEST AVAILABLE COPY

Patents Form 1/77

Patents Form 1/77

9. Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form

Description 7

Claim(s) 1

Abstract 1

Drawing(s)

10. If you are also filing any of the following, state how many against each item.

Priority documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (*Patents Form 7/77*)

Request for preliminary examination and search (*Patents Form 9/77*)

Request for substantive examination (*Patents Form 10/77*)

Any other documents
(please specify)

11.

I/We request the grant of a patent on the basis of this application

Signature

Date

B. A. Yorke & Co

B.A. Yorke & Co.

23 December 2002

12. Name and daytime telephone number of person to contact in the United Kingdom

Mrs. J. Crook

020 8560 5847

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

- a) If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.
- b) Write your answers in capital letters using black ink or you may type them.
- c) If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- d) Once you have filled in the form you must remember to sign and date it.
- e) For details of the fee and ways to pay please contact the Patent Office.

BEST AVAILABLE COPY

Patents Form 1/77

Organic Compounds

The present invention is related to orally administrable pharmaceutical compositions of macrolide antibiotics. Macrolide antibiotics are known. The "Merck Index" (12th ed., 1996) lists for instance erythromycin (no. 3720), roxithromycin (no. 8433), azithromycin (no. 946), josamycin (no. 5280), clarithromycin (no. 2400) and tylosin (no. 9963). Telithromycin is known from e.g. WO01/14393.

It is further known that drugs are advantageously orally administered in an alginate matrix comprising a water-soluble alginate and a complex salt of alginic acid as described in EP-A-188040 in order to achieve an extended release of the antibiotic so that the patients need to take the macrolide only once a day. This contributes a lot to the compliance of patients. However, one problem arising with the extended release formulations of macrolides in an alginate matrix is their poor solubility under alkaline conditions such as existing in the small intestine. Thus, resorption and bioavailability of orally administered macrolide antibiotics in extended release formulations are usually low in the small intestine. Therefore, it has been proposed in WO 97/22335 to include an organic acid such as citric acid into the extended release formulation of a poorly soluble basic drug in order to improve solubility and thus also bioavailability of the basic drug. However, these controlled release compositions do not purport to minimize the adverse effects related to gastrointestinal disorders including nausea and vomiting. In addition, said alginate matrix extended release formulations contain the organic acid such as citric acid in a molar ratio to the macrolide antibiotic of 1:1. As a consequence, considerable high amounts of organic acid is released from the formulation in the GI tract which is undesirable for patients with gastritis, ulcers and/or gastroesophageal reflux. As macrolides are often used in combination with proton pump-inhibitors such as for instance omeprazole, pantoprazole or lansoprazole, which are known to be very unstable under acidic conditions, it is not desirable to have released an organic acid from the alginate matrix formulation because it could contribute to the inactivation or degradation of the proton-pump inhibitor.

Thus, the aim of the present invention is to provide an improved orally administered alginate matrix formulation of a macrolide antibiotic which avoids a strong decrease of the pH value during release of the active ingredient.

This problem underlying the present invention is solved by adding to the extended release formulation comprising an alginate matrix an inorganic salt that is able to donate a proton

and exhibits a pK_a value in water from 4.0 to 9.0, preferably from 5.0 to 9.0, e.g. from 5.0 to 8.0.

Hence, in one aspect the present invention provides an orally administrable pharmaceutical composition comprising an alginate matrix consisting of a water-soluble alginate salt and a complex salt of alginic acid, a macrolide, and an inorganic salt characterized in that the inorganic salt is capable of donating a proton and has a pK_a value in water of 4.0 to 9.0.

The alginate matrix is formed as described in EP-A-188040 and consists of a water-soluble alginate and a complex salt of alginic acid. The water soluble alginate in a composition according to the present invention is typically an alkali metal salt of alginic acid such as a potassium or a sodium salt, or a magnesium or an ammonium salt of alginic acid. Preferred is a sodium alginate.

A complex salt of alginic acid in a composition according to the present invention is typically a sodium-calcium complex salt of alginic acid wherein the amount of calcium is precisely controlled and which is self-gelling without the necessity of reacting with the stomach acid or additional calcium ions. While sodium-calcium alginate is the preferred complex salt of alginic acid used in the present invention, the sodium ions may be replaced by another cation that yields a water-soluble alginate such as those mentioned above, e.g. potassium, other alkali metal, magnesium or ammonium. The calcium ion may be replaced by another polybasic cation which yields an insoluble alginate salt, e.g. iron, strontium or barium. Magnesium is not suitable as a polybasic cation.

The weight ratio of soluble alginate to complex salt of alginic acid may vary from about 16:1 to 1:1, preferably from about 8:1 to 2:1. The same ratio applies to the ratio of sodium alginate to sodium-calcium-alginate. Typically, the amount of soluble alginate in a composition varies from about 6% to about 25% of the total weight of the composition, and the amount of the complex salt of alginic acid varies from about 0.5% to about 10% of the total weight of the composition.

A composition according to the present invention comprises a macrolide antibiotic. Suitable macrolide antibiotics are any basic macrolide antibiotic, for example basic macrolide antibiotics having a solubility in water of less than 33 g/l at room temperature. Suitable macrolides are in particular those mentioned above, i.e. erythromycin, roxithromycin, azithromycin, josamycin, clarithromycin, tylosin or telithromycin. In a preferred embodiment

of the present invention the macrolide is clarithromycin. The amount of macrolide may vary in the composition from about 40%, preferably from about 50% to about 65%, preferably to about 75% of the total weight of the composition.

A composition according to the present invention comprises an inorganic salt that is capable of donating at least one proton and that has a pK_a value in water at 25°C of 4.0 to 9.0.

The pK_a value is defined as the negative logarithm of the dissociation constant K_a of an acidic compound dissolved in water at 25°C and the pK_a value is determined as conventional, e.g. according to known methods under standard conditions.

Preferably the pK_a value of an inorganic salt in water according to the present invention is from 5.0 to 9.0, e.g. from 5.0 to 8.0. Suitable salts are for instance hydrogensulfates, e.g. of an alkali metal or an earthalkaline metal, dihydrogenphosphates, e.g. of an alkali metal or an earthalkaline metal, such as sodium dihydrogenphosphate, potassium dihydrogenphosphate, sodium hydrogensulfate or potassium hydrogensulfate. In a preferred embodiment a composition of the present invention comprises potassium dihydrogenphosphate as an inorganic salt which is capable to donate a proton and has a pK_a value of 4.0 to 9.0.

The inorganic salt is present in a composition according to the present invention in an amount corresponding to a ratio of inorganic salt: macrolide of 1:2 to 1:100 on a weight basis. Typically, a formulation according to the present application comprises about 20 to about 160 mg of the inorganic salt per 500 mg of the macrolide. Preferably, the inorganic salt is present in an amount of about 80 mg per 500 mg of the macrolide.

A composition according to the present invention may be any orally administrable pharmaceutical composition, in particular a tablet, a capsule or a pellet, such as a tablet. In a preferred embodiment, the composition is a once daily administrable formulation, e.g. a tablet for once daily administration regimen.

A composition according to the present invention, e.g. a tablet may comprise additional ingredients such as one or more further active drug compound(s) and/or pharmaceutically acceptable excipients such as conventionally used in the preparation of macrolide formulations, for example a binder, e.g. polyvinyl pyrrolidone, hydroxypropylcellulose, sodium carboxymethylcellulose, a filler, e.g. lactose, dicalciumphosphate, mannitol, starch, microcrystalline cellulose, a glidant/lubricant, e.g. talcum, magnesiumstearate, stearic acid, and/or a preservative, e.g. potassium sorbate. The composition may additionally comprise flavoring, coloring and light-protecting agents, e.g. vanillin, titanium dioxide. The amounts of excipients in the composition depend on the specific formulation and are as conventional in

pharmaceutical formulations of macrolides. A tablet may be coated by conventional coating agents such as hydroxypropylmethylcellulose (e.g. Opadry®), e.g. in order to mask a bitter taste of the composition.

A composition according to the present invention may be prepared according to a known method, e.g. by a process comprising the steps of mixing a macrolide with a water-soluble alginate salt, a complex salt of alginic acid, an inorganic salt that has a pK_a -value in aqueous solution of 4.0 to 9.0 and that is capable of donating a proton, and optionally with pharmaceutically acceptable excipients. The mixture may be granulated according to conventional granulation technology, e.g. by adding water, and by drying the obtained granules using conventional drying technology. The dried granules may optionally be resized, e.g. by sieving. In case the composition is a capsule, the granules are filled into a capsule, e.g. a gelatine capsule. In case the composition is a tablet, the granules may be mixed with glidants/lubricants and compressed into tablets analogous to, e.g. according to technologies as conventional. If desired, a tablet core may be coated with known coating agents analogously, e.g. according to known methods.

A unit dosage form of a composition of the present invention comprises from 100 mg to 2000 mg of a macrolide antibiotic. Preferably, a once daily administered dosage form comprises from 250mg to 1000 mg of a macrolide antibiotic.

A composition according to the present invention avoids a strong pH decrease during release as it occurs with formulations according to the prior art comprising an organic acid, e.g. according to WO97/22335. Table 1 shows a comparison of the pH values during dissolution in water of a tablet comprising 500 mg clarithromycin and either A) an equimolar amount of citric acid (as described in the prior art, e.g. WO97/22335), or B) 80 mg of potassium dihydrogenphosphate (according to the present invention) under identical conditions:

Table 1: comparison of pH values in water during release of a tablet according to the present invention (B) and a tablet according to prior art (A)

pH in water	tablet A comprising citric acid	tablet B comprising KH_2PO_4
after 5 minutes	pH 4.9	pH 6.1
after 30 minutes	pH 4.5	pH 6.3
after 60 minutes	pH 4.4	pH 6.4
after 120 minutes	pH 4.3	pH 6.5

This effect has special advantages when a macrolide antibiotic composition according to the present invention is combined with a proton pump inhibitor. Macrolide antibiotics are often combined with proton pump inhibitors, such as omeprazole, lansoprazole or pantoprazole in the treatment of gastritis, gastrointestinal ulcers and/or gastroesophageal reflux diseases in order to increase the pH of gastric juices. Proton pump inhibitors are highly unstable under acidic conditions. Therefore, a composition according to the present invention may contribute to decrease the risk of inactivation or degradation of proton-pump inhibitors. In addition, it is generally not desirable to introduce additional acidic compounds into gastric juices of patients suffering in gastritis, gastrointestinal ulcers and/or gastroesophageal reflux diseases. As can be seen from table 1, a composition of the present invention lowers the pH during release to a much less extent than macrolide antibiotic compositions according to the prior art which comprise an organic acid.

In a preferred embodiment, the present invention relates to a film coated tablet comprising 500 mg clarithromycin, from about 80 mg to about 150 mg sodium alginate, from about 5 mg to about 50 mg sodium-calcium alginate, from about 20 mg to about 160 mg potassium dihydrogen phosphate, from about 30 mg to about 60 mg povidone (K=30), from about 100 mg to about 300 mg lactose monohydrate, from about 100 mg to about 300 mg dicalcium phosphate, from about 20 mg to about 30 mg talcum, and from about 10 mg to about 20 mg magnesium stearate.

The following Example demonstrates the present invention but shall in no way be construed to limit its scope.

Example:

A film coated tablet was prepared according to the following process:

Sr. no.	Ingredient	mg/tab	g / batch
1.	Clarithromycin	500	5.000
2.	Sodium alginate (Manucol LKX)	120	1.200
3.	Sodium –Calcium alginate (Kelset)	30	300
4.	Potassium dihydrogen phosphate	80	800
5.	Povidone (K=30)	30	300
6.	Lactose monohydrate	120	1.200
8.	Talc	30	300
9.	Magnesium stearate	10	100
10.	Opadry yellow	20	200
	Film coated tablet wt.	940	

Components 2, 3, 4, 5 and 6 were screened through a 425 μ aperture screen. The sieved excipients were dry blended with the API (component 1) in a high shear mixer. The blended material was granulated using water to obtain granules. The granules were dried in a fluidised bed drier at 60°C until the granules had a moisture content of less than 4.0 % w/w. (105 °C ,15 min). The dried granules were resized using a 850 μ aperture screen and then blended with lubricants (component 8 and 9) in a double-cone blender. The lubricated tablet blend was compressed into tablets using a rotary tablet machine. The core tablets were coated in a conventional perforated coating pan using an aqueous suspension of Opadry.

The controlled release of clarithromycin was determined by the in vitro dissolution profile in comparison to a tablet of clarithromycin on the market:

Medium : 900 ml Acetate buffer pH 5.0 , 50 RPM , Paddle type

time [h]	tablet according to the present invention	tablet according to WO97/22335
2	9	6
4	21	18
6	32	31
8	43	43
10	52	53
12	60	61
16	71	72
24	87	86

The decrease of pH value during dissolution in water of a tablet obtained from the above described process is compared under identical conditions to a dissolution of a tablet according to WO97/22335 comprising 500 mg clarithromycin and an equimolar amount of citric acid:

pH in water	tablet comprising citric acid	tablet comprising KH_2PO_4
after 5 minutes	pH 4.9	pH 6.1
after 30 minutes	pH 4.5	pH 6.3
after 60 minutes	pH 4.4	pH 6.4
after 120 minutes	pH 4.3	pH 6.5

Claims

1. An orally administrable pharmaceutical composition comprising an alginate matrix consisting of a water-soluble alginate salt and a complex salt of alginic acid, a macrolide, and an inorganic salt characterized in that the inorganic salt is capable of donating a proton and has a pK_a value in water of 4.0 to 9.0.
2. A composition according to claim 1 wherein the water-soluble alginate salt is an alkali metal salt of an alginate.
3. A composition according to claim 1 wherein the complex salt of alginic acid is sodium-calcium alginate.
4. A composition according to claim 1 wherein the macrolide is selected from the group consisting of erythromycin, roxithromycin, azithromycin, josamycin, telithromycin, clarithromycin and tylosin.
5. A composition according to claim 4 wherein the macrolide is clarithromycin.
6. A composition according to claim 1 wherein the inorganic salt has a pK_a value of 5.0 to 8.0.
7. A composition according to claim 1 wherein the inorganic salt is an alkali metal or earth-alkaline dihydrogenphosphate or hydrogensulfate.
8. A composition according to claim 1 wherein the ratio of inorganic salt : macrolide is from 1:2 to 1:100 on a weight basis.
9. A composition according to claim 1 wherein the pharmaceutical composition is a tablet for once daily administration.
10. Process for preparing a once daily orally administrable formulation of a macrolide by mixing the macrolide with a water-soluble alginate salt, a complex salt of alginic acid, and an inorganic salt that has a pK_a value in water of 4.0 to 9.0 and that is capable to donate a proton.

Abstract

The invention relates to an improved extended release orally administrable pharmaceutical composition comprising an alginate matrix consisting of a water-soluble alginate salt and a complex salt of alginic acid, a macrolide, and an inorganic salt characterized in that the inorganic salt is capable of donating a proton and has a pK_a value in water of 4.0 to 9.0.

